Human sTNF RII/TNFRSF1B Standard (人肿瘤坏死因子受体II 标准品)
¥280.00
- 分子靶点:TNFRSF1B, TNFR2, CD120b
- 种属:人 (Human)
- 试剂盒:EK1123
- 保存:短期4℃保存,长期-20℃保存
- 运输条件:4℃蓝冰运输
在售SKU:70-EK1123S
文章目录[隐藏]
本产品只包含标准品试剂,如需购买试剂盒请点击下图
-
- EK1123
- ELISA试剂盒
Human sTNF RII/TNFRSF1B ELISA Kit检测试剂盒(酶联免疫吸附法)
- ¥1,600.00 – ¥2,650.00
商品名 |
Human sTNF RII/TNFRSF1B Standard (人肿瘤坏死因子受体II 标准品) |
---|---|
组分 |
人sTNF RII/TNFRSF1B 标准品 |
板式 |
管 |
保存 |
短期4℃,长期-20℃保存 |
运输条件 |
4℃蓝冰运输 |
分子信息
TNFRSF1B 分子靶点信息概述
- 分子名:TNFRSF1B, TNF receptor superfamily member 1B
- 基因家族:CD molecules; Tumor necrosis factor receptor superfamily; MicroRNA protein coding host genes
- 别名:TNFBR; TNFR80; TNF-R75; TNF-R-II; p75; CD120b
- 曾用名:TNFR2
- 全称:tumor necrosis factor receptor superfamily, member 1B
TNFRSF1B 分子靶点综述
肿瘤坏死因子受体II (TNF RII)也称为肿瘤坏死因子受体超家族成员1B (TNFRSF1B)。该蛋白与TNF RI形成异源复合物,介导两种具有E3泛素连接酶活性的抗凋亡蛋白c-IAP1和c-IAP2的招募。IAPs在TNF受体信号传导中的功能尚未知,然而c-IAP1被认为通过泛素化和降解介导抗凋亡信号的TNF受体相关因子2 (TRAF2)来增强TNF诱导的凋亡。小鼠的基因敲除实验表明,该蛋白通过刺激抗氧化通路来保护神经元不发生凋亡的过程中发挥了作用。
人 Human TNFRSF1B 分子靶点信息
- 分子名:TNFRSF1B, TNF receptor superfamily member 1B
- 别称:
- CD120b
- p75
- p75 TNF receptor
- p75TNFR
- p80 TNF-alpha receptor
- soluble TNFR1B variant 1
- TBPII
- TNF-R-II
- TNF-R2
- TNF-R75
- TNF-RII
- TNFBR
- TNFR-II
- TNFR1B
- TNFR2
- TNFR80
- tumor necrosis factor beta receptor
- tumor necrosis factor binding protein 2
- tumor necrosis factor receptor 2
- tumor necrosis factor receptor superfamily member 1B
- tumor necrosis factor receptor superfamily, member 1B
- tumor necrosis factor receptor type II
- 基因序列:NCBI_Gene: 7133
- 蛋白序列:UniProtKB: P20333
人 Human TNFRSF1B靶点分子功能(预测)
Enables tumor necrosis factor binding activity and ubiquitin protein ligase binding activity. Involved in cellular response to lipopolysaccharide and positive regulation of membrane protein ectodomain proteolysis. Located in membrane raft. Implicated in several diseases, including Parkinsonism; acne; bone disease (multiple); glomerulonephritis (multiple); and lung disease (multiple). Biomarker of several diseases, including autoimmune disease of musculoskeletal system (multiple); female reproductive organ cancer (multiple); glomerulonephritis (multiple); kidney failure (multiple); and lung disease (multiple).